---
title: Economic Analysis
description: Comprehensive cost-benefit analysis demonstrating 463:1 to 1,239:1 return on investment through military budget redirection to medical research.
published: true
tags:
  - economics
  - cost-benefit-analysis
  - public-health
  - peace-dividend
  - roi
  - impact-assessment
  - health-economics
lastFormatted: '2025-10-16T00:00:00.000Z'
lastStyleCheck: '2025-10-16T00:00:00.000Z'
lastParamCheckHash: c6c1adaae3f668e0729df5aa12f73a0ddedccc987de87895bcc8ca8701b1864c
lastInstructionalVoiceHash: b9c8c2b1470bfa6c6b8afc9d3f84774ad579f4f2d4a0111bc3b252770d7966e9
---
```{python}
#| echo: false
from dih_models.parameters import *

```

<!-- ✓ Style reviewed 2025-01-15 -->

## Executive Summary

Here's how you get 463:1 to 1,239:1 returns on redirecting 1% of murder money ([$27.2B/year](../appendix/peace-dividend-calculations.qmd)) to not-murder money.

The beautiful part: it costs zero new dollars. You're just moving money from the "making corpses" column to the "preventing corpses" column in the budget spreadsheet.

You get paid twice for the same 1% shift:

1. **Peace dividend**: [{{< var peace_dividend_annual_societal_benefit >}}/year](../appendix/peace-dividend-calculations.qmd) appears when you build 1% fewer bombs (turns out bombs are expensive and breaking things costs money to fix)
2. **Research efficiency**: [{{< var dfda_gross_savings_annual >}}+/year](../appendix/dfda-cost-benefit-analysis.qmd) saved by not drowning scientists in paperwork (Oxford proved trials cost [82x less](../appendix/recovery-trial.qmd) when you stop requiring 17 years of documentation)

### The Numbers

- **Conservative returns**: [463:1](../appendix/dfda-cost-benefit-analysis.qmd) (counting only R&D savings, ignoring everything else)
- **Realistic returns**: {{< var roi_all_direct_benefits >}}:1 (counting all eight measurable benefits)
- **Per life saved**: Society MAKES [$6.56M](../appendix/1-percent-treaty-cost-effectiveness.qmd) (vs. best charities SPENDING [$3,500-5,500](../references.qmd#givewell-cost-per-life-saved))
- **Lives saved yearly**: [{{< var treaty_total_lives_saved_annual >}}](../appendix/1-percent-treaty-cost-effectiveness.qmd) (lowball estimate)

## How the Math Works

### The Approach

Standard economic analysis, nothing fancy:

- Discount future money at 5% (economists insist on this)
- Count quality-adjusted life years (economist-speak for "being alive and not miserable")
- Compare cost per outcome to other interventions
- Test what happens if we're wrong about everything (see [sensitivity analysis](../appendix/1-percent-treaty-cost-effectiveness.qmd))

The calculations are conservative and validated against the [Oxford RECOVERY trial](../appendix/recovery-trial.qmd), which proved 82x cost reduction by not requiring 40,000 pages of paperwork per patient.

### Two Ways to Count

**463:1 = Pessimistic (R&D Savings Only)**

Count only the $50.0B/year saved from 82x cheaper trials. Pretend everything else doesn't exist. This is the floor. This is what you tell skeptical accountants.

**{{< var roi_all_direct_benefits >}}:1 = Realistic (All Eight Benefits)**

Count all {{< var total_complete_benefits_annual >}}/year in measurable benefits: peace dividend, R&D savings, earlier access, research acceleration, rare disease treatments, drug price reductions, prevention, and mental health. This is what actually happens.

### Which Number to Use

**Use 463:1** when talking to:
- Risk-averse investors who trust nothing
- Regulators paid to say "no"
- People who think optimism is a character flaw

**Use {{< var roi_all_direct_benefits >}}:1** when talking to:
- Anyone who can count to eight
- Foundation grant reviewers
- People interested in reality

Both use the same math. One just counts more stuff.

## The Conservative Case: 463:1 ROI (dFDA Only)

Here's the floor. Count only R&D savings from cheaper trials. Ignore peace dividends, earlier access, and everything else that makes this look "too good to be true."

### The Math

Basic division:

$$
\text{ROI} = \frac{\text{Benefits}}{\text{Costs}} = \frac{\$249.3\text{B}}{\$538\text{M}} = 463:1
$$

where [$249.3B](../appendix/dfda-cost-benefit-analysis.qmd) is what you save over 10 years and [{{< var dfda_npv_total_cost >}}](../appendix/dfda-cost-benefit-analysis.qmd) is what you spend to build it.

This uses "net present value" which is economist code for "future money is worth less than current money" (5% discount rate, 10-year horizon). For the spreadsheet addicts: [full NPV methodology here](../appendix/dfda-cost-benefit-analysis.qmd#calculation-framework---npv-methodology).

### Where the Money Comes From

1% of global military budgets gets redirected. This gives you:

- **Funding**: [$27.2B/year](../appendix/peace-dividend-calculations.qmd) to spend on not-dying
- **Bonus savings**: [{{< var peace_dividend_annual_societal_benefit >}}/year](../appendix/peace-dividend-calculations.qmd) in economic value from building 1% fewer things that explode

The peace dividend math is simple: wars cost [$11.355T/year](../appendix/peace-dividend-calculations.qmd). 1% less war costs 1% less money.

$$
\$11{,}355\text{B} \times 1\% = \$113.6\text{B}
$$

| Cost Category | Annual Amount | Components |
|:---|---:|:---|
| **Direct Military Spending** | [$2,718B](../references.qmd#sipri-2024-spending) | SIPRI 2024 global military budgets |
| **[Infrastructure Destruction](../appendix/peace-dividend-calculations.qmd)** | [$1,875B](../appendix/peace-dividend-calculations.qmd) | Transportation, energy, communications, water, education, healthcare facilities |
| **Human Life Losses** | [$2,446B](../appendix/peace-dividend-calculations.qmd) | [{{< var global_annual_conflict_deaths_total >}} conflict deaths](../references.qmd#acled-active-combat-deaths) × [{{< var value_of_statistical_life >}} value of statistical life](../references.qmd#dot-vsl-13-6m) (conservative vs. DOT $13.7M) |
| **[Trade Disruption](../appendix/peace-dividend-calculations.qmd)** | [{{< var global_annual_trade_disruption_conflict >}}](../appendix/peace-dividend-calculations.qmd) | Shipping, supply chains, energy prices, currency volatility |
| **[Lost Economic Growth](../appendix/peace-dividend-calculations.qmd)** | [$2,718B](../appendix/peace-dividend-calculations.qmd) | Opportunity cost of military spending vs. productive investment |
| **[Veteran Healthcare](../appendix/peace-dividend-calculations.qmd)** | [{{< var sensitivity_peace_dividend_optimistic >}}](../appendix/peace-dividend-calculations.qmd) | Long-term medical care for conflict-related injuries |
| **Refugee Support** | {{< var global_annual_refugee_support_costs >}} | [108.4M displaced persons](../references.qmd#unhcr-forcibly-displaced-2023) × $1,384/year |
| **[Environmental Damage](../appendix/peace-dividend-calculations.qmd)** | [{{< var global_clinical_trial_market_annual >}}](../appendix/peace-dividend-calculations.qmd) | Environmental destruction, toxic contamination, restoration costs |
| **[Psychological Impact](../appendix/peace-dividend-calculations.qmd)** | [{{< var global_annual_psychological_impact_costs_conflict >}}](../appendix/peace-dividend-calculations.qmd) | PTSD treatment, mental health services, productivity loss |
| **[Lost Human Capital](../appendix/peace-dividend-calculations.qmd)** | [{{< var global_annual_lost_human_capital_conflict >}}](../appendix/peace-dividend-calculations.qmd) | Productive capacity lost from casualties and displacement |
| **Total War Costs** | **$11,355B** | Combined direct and indirect annual costs |
| **1% Reduction** | **{{< var peace_dividend_annual_societal_benefit >}}** | Peace dividend from 1% treaty implementation |

This calculation methodology follows standard cost-of-conflict analysis frameworks used by the World Bank, IMF, and academic conflict economics research. See [Peace Dividend Calculations](../appendix/peace-dividend-calculations.qmd) for detailed sources and methodology.

### What It Costs to Build

**Total**: [{{< var dfda_npv_total_cost >}}](../appendix/dfda-cost-benefit-analysis.qmd) over 10 years (present value)
  - Upfront: [{{< var dfda_npv_upfront_cost_total >}}](../appendix/dfda-cost-benefit-analysis.qmd) (build the platform)
  - Yearly operations: [{{< var dfda_upfront_build >}}](../appendix/dfda-cost-benefit-analysis.qmd) (keep it running)

The [$27.2B/year](../appendix/peace-dividend-calculations.qmd) peace dividend covers [{{< var dfda_upfront_build >}}/year](../appendix/dfda-cost-benefit-analysis.qmd) operations **680 times over**. It's like having $680 to pay a $1 bill.

This assumes gradual rollout (0% to 100% over 5 years) and middle-range costs. For the detailed breakdown see [dFDA Cost-Benefit Analysis](../appendix/dfda-cost-benefit-analysis.qmd#costs-of-building-and-operating-the-global-decentralized-fda-rom-estimate).

### What You Get Back

- **Money**: [$249.3B](../appendix/dfda-cost-benefit-analysis.qmd) in R&D savings (10 years, present value)
- **Returns**: [$249.3B](../appendix/dfda-cost-benefit-analysis.qmd) ÷ [{{< var dfda_npv_total_cost >}}](../appendix/dfda-cost-benefit-analysis.qmd) = **[463:1](../appendix/dfda-cost-benefit-analysis.qmd)**
- **People not dying**: [{{< var global_dfda_qalys_gained_annual >}} quality-adjusted life years](../appendix/1-percent-treaty-cost-effectiveness.qmd) annually

**Two income streams from one budget shift**:

1. **Peace dividend**: [{{< var peace_dividend_annual_societal_benefit >}}/year](../appendix/peace-dividend-calculations.qmd) saved by not breaking as much stuff
2. **Research efficiency**: [$50.0B/year](../appendix/dfda-cost-benefit-analysis.qmd) saved by not requiring PhDs to fill out forms for 17 years

**Combined**: [{{< var combined_peace_health_dividends_annual_for_roi_calc >}}/year](../appendix/dfda-cost-benefit-analysis.qmd) (conservative, ignoring most benefits)

**If everything goes wrong**: Worst-case scenario (benefits half as good, costs twice as high) still delivers [189:1 to {{< var optimistic_scenario_roi >}}:1](../appendix/1-percent-treaty-cost-effectiveness.qmd) returns. See [sensitivity analysis](../appendix/1-percent-treaty-cost-effectiveness.qmd).

### Cost-Effectiveness: Dominant Health Intervention

Unlike traditional public health interventions that require ongoing funding, the 1% Treaty represents a **dominant intervention**, simultaneously reducing costs while improving health outcomes. This places it in a unique category alongside smallpox eradication and other transformative health achievements.

#### Incremental Cost-Effectiveness Ratio (ICER)

The ICER measures cost per quality-adjusted life year (QALY) gained:

$$
\text{ICER} = \frac{\Delta \text{Cost}}{\Delta \text{QALYs}} = \frac{C_{\text{intervention}} - C_{\text{baseline}}}{Q_{\text{intervention}} - Q_{\text{baseline}}}
$$

For the dFDA Infrastructure (using annual figures):

$$
\text{ICER} = \frac{\text{Net Incremental Cost (Annual)}}{\text{QALYs Gained (Annual)}} = \frac{-\$49.96\text{B}}{840{,}000 \text{ QALYs}} = -\$59{,}476 \text{ per QALY}
$$

where the net incremental cost is calculated as platform operational costs ([{{< var dfda_upfront_build >}}/year](../appendix/dfda-cost-benefit-analysis.qmd)) minus R&D savings ([$50.0B/year](../appendix/dfda-cost-benefit-analysis.qmd)) = -$49.96B annually, and [{{< var global_dfda_qalys_gained_annual >}} QALYs](../appendix/1-percent-treaty-cost-effectiveness.qmd) represents annual quality-adjusted life years gained.

The negative ICER indicates **cost savings while improving health**, a dominant intervention by health economics standards. Standard [willingness-to-pay thresholds are $50,000-$150,000 per QALY](../references.qmd#icer-qaly-methodology); interventions that save costs while gaining QALYs are unconditionally recommended.

**For comprehensive ICER analysis including sensitivity analysis across multiple scenarios, alternative funding perspectives, and detailed methodology**, see [dFDA ICER Analysis](../appendix/dfda-cost-benefit-analysis.qmd#dfda-icer-analysis---cost-utility-framework).

#### Comparative Cost per Life Saved

- **[Against Malaria Foundation](../references.qmd#givewell-cost-per-life-saved)**: $3,500 cost per life saved (GiveWell top charity)
- **[Deworm the World Initiative](../references.qmd#givewell-cost-per-life-saved)**: $5,500 cost per life saved (highly cost-effective intervention)
- **1% Treaty/dFDA System**: [$6,560,000 net societal benefit](../appendix/1-percent-treaty-cost-effectiveness.qmd) per life saved (dominant intervention)

The negative cost (net benefit) per life saved distinguishes this as a dominant intervention in health economics terminology, an intervention that both reduces costs and improves outcomes, with no trade-off between efficiency and effectiveness.

### This ROI in Historical Context

The Decentralized FDA alone achieves **463:1 return on investment**.

This exceptional ROI comes from:

- **$50.0B in annual R&D cost savings**: [82x reduction](../appendix/recovery-trial.qmd) in clinical trial costs
- **Faster access to new treatments**: [2 years instead of 17 years](../appendix/dfda-cost-benefit-analysis.qmd) to market
- **Better prevention through real-world data**: Continuous learning from millions of patients
- **Enabling new therapies**: Making [rare disease trials](../references.qmd#rare-disease-patients-300m-globally) economically viable

{{< include ../figures/health-interventions-roi-comparison-column-chart.qmd >}}

Comparison to historical public health achievements (ROI ratios):

| Intervention | ROI | Source |
|:---|---:|:---|
| **1% Treaty/dFDA** | **463:1** | This analysis |
| [Smallpox eradication](../references.qmd#smallpox-eradication-roi) | 159-400:1 | WHO intensive campaign (1967-1980) |
| [Clean water & sanitation](../references.qmd#clean-water-sanitation-roi) | 4-21:1 | WHO/WaterAid (LMICs) |
| [Childhood vaccinations](../references.qmd#childhood-vaccination-roi) | 10-16:1 | CDC immunization economic analyses |
| Average pharma drug | 2:1 | Industry standard (Tufts CSDD) |

The 1% Treaty/dFDA system **rivals or exceeds the ROI of smallpox eradication**, previously considered the gold standard of public health interventions. For detailed comparisons across all major health interventions, see [Intervention Comparison Table](../appendix/intervention-comparison-table.qmd).

### Self-Funding Mechanism Through Military Budget Redirection

{{< include ../figures/self-funding-roi-comparison-column-chart.qmd >}}

The 1% Treaty financing structure creates a self-funding system requiring zero net new spending from donors or taxpayers.

**Economic Structure** ([see detailed calculation](../appendix/1-percent-treaty-cost-effectiveness.qmd)):

- **Funding Source**: [$27.2B annually](../appendix/peace-dividend-calculations.qmd) from 1% redirection of existing military budgets (money already allocated in national budgets)
- **Annual Benefits**: [{{< var combined_peace_health_dividends_annual_for_roi_calc >}}](../appendix/dfda-cost-benefit-analysis.qmd) (Peace dividend: [{{< var peace_dividend_annual_societal_benefit >}}](../appendix/peace-dividend-calculations.qmd) + R&D savings: [$50.0B](../appendix/dfda-cost-benefit-analysis.qmd))
- **Operating Costs**: [{{< var treaty_total_annual_costs >}} annually](../appendix/dfda-cost-benefit-analysis.qmd) (campaign operations and dFDA infrastructure)
- **Net Position**: [$163.3B annual surplus](../appendix/dfda-cost-benefit-analysis.qmd) after all costs
- **Lives Saved**: [{{< var treaty_total_lives_saved_annual >}} annually](../appendix/1-percent-treaty-cost-effectiveness.qmd)

$$
925{,}610 \text{ QALYs} \div 35 \text{ QALYs/life} = 26{,}446 \text{ lives}
$$

- **Cost per Life Saved**: Net societal benefit of `{python} cost_per_life_investor_funded_formatted` per life ([negative cost](../appendix/1-percent-treaty-cost-effectiveness.qmd) indicates net profit)

This financing structure classifies the 1% Treaty as a **dominant health intervention** using standard health economics terminology, an intervention with both lower costs and better health outcomes than the status quo, requiring no trade-off between cost-effectiveness and impact.

The self-funding nature eliminates traditional barriers to scale, as the intervention generates sufficient economic surplus to sustain and expand operations without ongoing charitable contributions.

## The Complete Case: {{< var roi_all_direct_benefits >}}:1 ROI (All Direct Benefits)

The conservative 463:1 calculation deliberately excludes most system benefits to establish a defensible floor. A comprehensive analysis including all eight quantifiable primary benefit categories demonstrates substantially higher returns.

### {{< var total_complete_benefits_annual >}} in Annual Benefits

The complete benefit framework encompasses eight measurable categories. Total annual benefit $B_{\text{total}}$ is calculated as:

$$
B_{\text{total}} = \sum_{i=1}^{8} B_i = B_{\text{peace}} + B_{\text{R\&D}} + B_{\text{access}} + B_{\text{research}} + B_{\text{rare}} + B_{\text{prices}} + B_{\text{prevention}} + B_{\text{mental}}
$$

where each benefit category is:

1. **Peace dividend** ([{{< var peace_dividend_annual_societal_benefit >}}](../appendix/peace-dividend-calculations.qmd)) - Societal savings from 1% less conflict
2. **R&D cost savings** ([$50.0B](../appendix/dfda-cost-benefit-analysis.qmd)) - 82x cheaper trials
3. **7-year access acceleration** ([$300.0B](../appendix/economic-value-of-accelerated-treatments.qmd)) - Earlier treatment access during trials
4. **Research acceleration** ([$100.0B](../appendix/research-acceleration-model.qmd)) - 115X more research capacity (10-20X more breakthroughs)
5. **Rare disease treatments** ($400.0B) - Economically viable orphan drug development for [300M patients](../references.qmd#rare-disease-patients-300m-globally) with diseases lacking treatments ([95% of 7,000+ rare diseases](../references.qmd#95-pct-diseases-no-treatment) have no FDA-approved therapy)
6. **Drug price reductions** ($100.0B) - Conservative estimate based on [U.S. drug prices 2.78x higher](../references.qmd#us-drug-prices-vs-peer-countries) than peer countries ($360B annual U.S. spending; 20-50% reduction potential = $72-180B from U.S. alone)
7. **Prevention medicine** ($100.0B) - Based on [global clinical trial market](../appendix/global-clinical-trial-spending-by-phase.qmd) projections exceeding {{< var global_clinical_trial_market_annual >}} annually, enabling economically viable prevention studies
8. **Mental health** ($75.0B) - Conservative partial closure of [{{< var sensitivity_peace_dividend_optimistic >}} funding gap](../references.qmd#mental-health-nonprofit-grants) identified for global mental health care needs

$$
B_{\text{total}} = 113.6 + 50.0 + 300.0 + 100.0 + 400.0 + 100.0 + 100.0 + 75.0 = \$1,238.6\text{B} \approx \$1.2\text{T}
$$

#### Complete Case ROI

$$
\text{ROI}_{\text{complete}} = \frac{\$1,238.6\text{B annual} \times 10\text{ years}}{\$1.0\text{B implementation}} = 1,239:1
$$

where [$1,238.6B](../appendix/dfda-cost-benefit-analysis.qmd) is the total annual benefit across all eight categories, 10 years is the NPV-adjusted time horizon, and [$1.0B](campaign-budget.qmd) is the total implementation cost. The two largest contributors—**earlier access acceleration** and **research capacity expansion**—are often misunderstood as the same thing. They're not:

- **Earlier Access** = Patients access the SAME treatments 7 years sooner (during trials instead of post-approval)
- **Research Acceleration** = System runs 115X MORE trials, finding 10-20X MORE breakthroughs

Both are conservative estimates based on proven models ([RECOVERY trial](../appendix/recovery-trial.qmd) costs, disease prevalence data, standard QALY valuations).

### Research Acceleration Mechanism: How We Get 115X

The 115x research acceleration multiplier is derived from specific, measurable improvements across four dimensions:

**Current System Baseline**:

- [{{< var current_trials_per_year >}} clinical trials initiated per year](../appendix/research-acceleration-model.qmd)
- [60% completion rate](../appendix/research-acceleration-model.qmd) = **[{{< var current_completed_trials_per_year >}} completed trials/year](../appendix/research-acceleration-model.qmd)**
- [10,000 active trials](../appendix/research-acceleration-model.qmd) at any time (3-5 year duration)
- [0.2% patient eligibility](../appendix/clinical-trial-participants.qmd) (5M trial slots for [2.4B people with chronic disease](../references.qmd#disease-prevalence-2-billion))
- [40% abandonment rate](../appendix/research-acceleration-model.qmd) (studies never complete)
- [6-18 months to recruit 100 patients](../appendix/research-acceleration-model.qmd)

**dFDA System Performance**:

- [{{< var dfda_trials_per_year_capacity >}} trials/year capacity](../appendix/research-acceleration-model.qmd)
- [95% completion rate](../appendix/research-acceleration-model.qmd) = **[{{< var dfda_completed_trials_per_year >}} completed trials/year](../appendix/research-acceleration-model.qmd)**
- [200,000 active trials](../appendix/research-acceleration-model.qmd) at any time (3-12 month duration)
- [50% patient eligibility](../appendix/research-acceleration-model.qmd) ([1.2B eligible](../appendix/research-acceleration-model.qmd) with minimal exclusions)
- [5% abandonment rate](../appendix/research-acceleration-model.qmd) (economic incentives flipped)
- [3 weeks to recruit {{< var traditional_large_trial_size >}} patients](../appendix/research-acceleration-model.qmd)

**Multiplier Derivation**:

| Factor | Current | dFDA | Multiplier |
|:---|---:|---:|---:|
| **[Recruitment Speed](../appendix/research-acceleration-model.qmd)** | 6-18 months for 100 patients | 3 weeks for {{< var traditional_large_trial_size >}} patients | **[25x](../appendix/research-acceleration-model.qmd)** |
| **[Trial Completion Speed](../appendix/research-acceleration-model.qmd)** | 3-5 years (perverse incentives) | 3-12 months (aligned incentives) | **[10x](../appendix/research-acceleration-model.qmd)** |
| **[Simultaneous Trials](../appendix/research-acceleration-model.qmd)** | 10,000 active trials | 200,000 active trials | **[20x](../appendix/research-acceleration-model.qmd)** |
| **[Completion Rate](../appendix/research-acceleration-model.qmd)** | 60% finish | 95% finish | **[1.6x](../appendix/research-acceleration-model.qmd)** |
| **Funding Increase** | [$67.5B medical research](../appendix/global-government-medical-research-spending.qmd) | [$94.7B](../appendix/research-acceleration-model.qmd) ($67.5B + $27.2B) | **[1.4x](../appendix/research-acceleration-model.qmd)** |

**Theoretical Maximum**:

$$
25 \times 10 \times 1.6 \times 1.4 = 560
$$

This represents **[560x](../appendix/research-acceleration-model.qmd)** more completed trials per year

**Conservative Estimate**: [180x](../appendix/research-acceleration-model.qmd) accounting for real-world friction (ramp-up, adoption, learning curves)

**Used in Analysis**: **[115x](../appendix/research-acceleration-model.qmd)** (further conservative adjustment for foundation grant proposal credibility)

This represents:

- From [{{< var current_completed_trials_per_year >}} completed trials/year](../appendix/research-acceleration-model.qmd) → [227,700 completed trials/year](../appendix/research-acceleration-model.qmd) (115x)
- From [50 drug approvals/year](../references.qmd#global-new-drug-approvals-50-annually) → [1,000-{{< var dfda_drug_approvals_per_year_high >}} approvals/year](../appendix/research-acceleration-model.qmd) (20-40x)
- From [$41,000 cost per patient](../appendix/recovery-trial.qmd) → [{{< var recovery_trial_cost_per_patient >}}-1,000 cost per patient](../appendix/research-acceleration-model.qmd) ([82x cost reduction](../appendix/recovery-trial.qmd), proven by Oxford RECOVERY trial)

**For detailed analysis including the 7-year access model, research capacity calculations, benefit breakdown table, and sanity checks**, see [Research Acceleration Model - Detailed Analysis](../appendix/research-acceleration-model.qmd).

## Personal Economic Impact: From Societal to Individual

The aggregate societal benefits ({{< var combined_peace_health_dividends_annual_for_roi_calc >}}-{{< var total_complete_benefits_annual >}} annually) result from individual economic gains multiplied across billions of people. Understanding individual impact helps explain both the scale and the equity of the Disease Eradication Model.

{{< include ../figures/disease-eradication-annual-benefits-stacked-area-chart.qmd >}}

For detailed analysis of personal wealth calculations, see [Disease Eradication Model: Personal Lifetime Wealth](../appendix/disease-eradication-personal-lifetime-wealth-calculations.qmd).

## Problem Statement and Opportunity Cost

### Current Resource Allocation

Global spending on health-related challenges demonstrates significant misalignment between resource allocation and burden of disease (see [Humanity's Budget](../appendix/humanity-budget-overview.qmd) for complete breakdown):

- **Military spending**: [$2.7 trillion annually](../references.qmd#sipri-2024-spending) ([40X](../appendix/humanity-budget-overview.qmd) [medical research funding](../appendix/global-government-medical-research-spending.qmd))
- **Symptomatic disease treatment**: [$8.2 trillion annually](../references.qmd#disease-economic-burden-109t) (primarily managing chronic conditions rather than curative interventions)
- **Economic burden of disease**: [$109 trillion annually](../references.qmd#disease-economic-burden-109t) in lost productivity, premature mortality, and disability-adjusted life years
- **Total annual cost**: [$119.8 trillion](../appendix/humanity-budget-overview.qmd)

**Current investment in curative research**:

- Global government medical research: [$68 billion annually](../appendix/global-government-medical-research-spending.qmd)

$$
\frac{\$68\text{B}}{\$119.8\text{T}} = 0.057\% \text{ of total disease burden}
$$

- Disease eradication achievements: Zero in past 50 years (since [smallpox, 1980](../references.qmd#smallpox-eradicated))
- Resource allocation ratio: 1:40 (medical research : military spending)

{{< include ../figures/military-vs-medical-research-spending-1-percent-treaty-column-chart.qmd >}}

### Mortality and Morbidity Burden

<!-- ![Annual deaths from disease (54,750,000) versus deaths from 9/11 Terrorist Attacks (2,996)](../../assets/deaths-from-disease-vs-deaths-from-terrorism-chart.png) -->

The World Health Organization reports [{{< var global_daily_deaths_curable_diseases >}} daily deaths](../references.qmd#who-daily-deaths) from preventable or potentially curable diseases ([54.75 million annually](../references.qmd#who-daily-deaths)). This mortality burden exceeds:

- [Annual terrorism deaths](../references.qmd#chance-of-dying-from-terrorism-1-in-30m) by a factor of [18,274:1](../references.qmd#chance-of-dying-from-terrorism-1-in-30m)

$$
\frac{54.75\text{M disease deaths}}{3{,}000\text{ terrorism deaths}} \approx 18{,}274:1
$$

- [Annual war deaths](../references.qmd#acled-active-combat-deaths) by a factor of 137:1 (based on [{{< var global_annual_conflict_deaths_total >}} conflict deaths](../references.qmd#acled-active-combat-deaths) annually)

$$
\frac{54.75\text{M disease deaths}}{400{,}000\text{ conflict deaths}} \approx 137:1
$$

Despite this disparity in mortality burden, resource allocation heavily favors security spending over medical research and curative interventions.

## How This Compares to History

### Better Than the Best Charities

Here's how it compares to the most effective charities in the world ([GiveWell top charities](../references.qmd#givewell-cost-per-life-saved)):

| Intervention | Cost to Achieve Outcome | This Initiative's Equivalent |
| :--- | :--- | :--- |
| **[GiveWell Top Charities](../references.qmd#givewell-cost-per-life-saved)** (e.g., Against Malaria Foundation) | Spend **~`{python} givewell_cost_per_life_min_formatted` - `{python} givewell_cost_per_life_max_formatted`** to save one life | Generate **[{{< var global_dfda_qalys_gained_annual >}} QALYs](../appendix/1-percent-treaty-cost-effectiveness.qmd)** annually while creating **[$249.3B](../appendix/dfda-cost-benefit-analysis.qmd)** in net economic value |

**The Difference**: GiveWell's charities are the best ways to spend money to save lives. They cost money but save lives very efficiently.

This plan doesn't cost money, it *makes* money while saving lives. Instead of asking people to donate, it makes everyone richer while curing diseases.

**Bottom line**: While the world's best charities spend `{python} givewell_cost_per_life_min_formatted`-`{python} givewell_cost_per_life_max_formatted` to save a life (which is excellent), the 1% Treaty + DIH + dFDA actually **SAVES society `{python} cost_per_life_investor_funded_formatted` per life saved**.

### Better Than History's Best Public Health Wins

| Intervention | How it Creates Value | Scale of Annual Net Benefit |
| :--- | :--- | :--- |
| **[Childhood Vaccinations](../references.qmd#childhood-vaccination-roi)** | Prevents immense long-term treatment costs for diseases like measles and polio | Billions to Tens of Billions |
| **Smoking Cessation** | Prevents expensive chronic diseases (cancer, heart disease) through low-cost interventions | Billions to Tens of Billions |
| **[Water & Sanitation](../references.qmd#clean-water-sanitation-roi)** | Avoids disease costs for entire populations at low cost | Hundreds of Millions to Billions |
| **[1% Treaty (Peace Dividend)](../appendix/peace-dividend-calculations.qmd)** | Reduces global conflict costs by 1%, creating massive economic benefit | **~113.6B, Annually** |
| **[dFDA (R&D Efficiency)](../appendix/dfda-cost-benefit-analysis.qmd)** | Makes clinical research ~82x more efficient, unlocking huge R&D savings | **~$50.0B, Annually** |

#### Why This Is Different

Vaccines and smoking cessation programs are amazing, they solve specific problems with a high return.

The 1% Treaty and dFDA initiative tackles two problems at once:

1. **The Peace Dividend** is a massive economic gain on par with the largest public health wins, created simply by reducing a global negative (conflict)
2. **The dFDA** then uses a tiny fraction of that gain to fix the *system* of medical research, generating a *second* massive win

Instead of solving one problem, this uses a global-scale win to fund a system-scale win. When you redirect the world's largest source of waste to fund its most impactful opportunity, the math gets wild.

### 10X Larger Than Childhood Vaccinations

{{< include ../figures/health-programs-vs-1-percent-treaty-societal-benefits-bar-chart.qmd >}}

The conservative case annual economic benefit of [{{< var combined_peace_health_dividends_annual_for_roi_calc >}}](../appendix/dfda-cost-benefit-analysis.qmd) significantly exceeds the most successful public health programs in history. Comparing to [childhood vaccination programs](../references.qmd#childhood-vaccination-roi) (estimated [10-20B annual global benefit](../references.qmd#childhood-vaccination-roi) from preventing measles, polio, etc.):

$$
\text{Relative Scale} = \frac{\$163.6\text{B}}{\sim\$15\text{B}} \approx 11:1
$$

where {{< var combined_peace_health_dividends_annual_for_roi_calc >}} is the [1% Treaty conservative case benefit](../appendix/dfda-cost-benefit-analysis.qmd) and $15B is the estimated [childhood vaccination annual benefit](../references.qmd#childhood-vaccination-roi).

This makes the 1% Treaty/dFDA system **[11X larger in economic impact](../appendix/intervention-comparison-table.qmd)** than childhood vaccinations, one of the most successful public health interventions ever implemented.

Unlike traditional interventions that require ongoing charitable funding, the 1% Treaty is **self-funding**: it generates [{{< var combined_peace_health_dividends_annual_for_roi_calc >}}](../appendix/dfda-cost-benefit-analysis.qmd) in annual economic surplus (conservative case) to sustain operations and expansion without requiring ongoing charitable contributions.

## The Opportunity Cost Clock

Every second we don't implement this system:

- **$38,051** in foregone economic value

$$
\frac{\$1.2\text{T}}{365 \text{ days} \times 24 \text{ hours} \times 3600 \text{ seconds}} = \$38{,}051/\text{second}
$$

- **1.736 preventable deaths** occur

$$
\frac{54.75\text{M deaths/year}}{365 \times 24 \times 3600 \text{ seconds}} = 1.736 \text{ deaths/second}
$$

**Daily Opportunity Cost**:

- **$3.3B** in foregone economic value

$$
\$1.2\text{T} \div 365 \text{ days} = \$3.3\text{B/day}
$$

- **{{< var global_daily_deaths_curable_diseases >}}** preventable deaths
- **{{< var global_daily_deaths_curable_diseases >}}** individuals experiencing curable disease burden
- **1.736 deaths per second** from addressable conditions

**Annual Opportunity Cost**:

- **{{< var total_complete_benefits_annual >}}** in foregone economic value (complete case benefit)
- **54.75 million** preventable deaths
- **$109T** in disease burden continues

These figures represent the mathematical consequence of maintaining current resource allocation patterns versus implementing the 1% Treaty system.

## Who Benefits and How

The 1% Treaty creates positive economic incentives across all major groups, eliminating traditional opposition to healthcare system reform. This alignment makes it politically feasible and sustainable.

**Who Gets What** (see [Aligning Incentives](../solution/aligning-incentives.qmd) for details):

- **Defense sector**: Keeps [99% of current budget](../appendix/peace-dividend-calculations.qmd) 
- **Pharmaceutical industry**: Trial costs shift from expense to revenue (patients fund participation); [research capacity increases 115X](../appendix/research-acceleration-model.qmd)
- **Insurance companies**: Net savings from [reduced disease burden](../references.qmd#disease-economic-burden-109t) ([$109T current economic cost](../references.qmd#disease-economic-burden-109t))
- **Healthcare providers**: More treatment options; [earlier access to effective therapies](../appendix/economic-value-of-accelerated-treatments.qmd)
- **Patients**: Access to clinical trials as healthcare and new treatments years or decades sooner
- **Taxpayers**: Net reduction in taxes and healthcare costs through improved R&D efficiency

See [Aligning Incentives](../solution/aligning-incentives.qmd) for detailed analysis and implementation strategy.

## Implementation Strategy

The economic benefits outlined above demonstrate the value proposition of the 1% Treaty system. Implementation requires political mobilization to achieve treaty adoption:

**For comprehensive implementation details**, see:

- **[Campaign Budget](campaign-budget.qmd)** - Detailed breakdown of political mobilization costs
- **[VICTORY Social Impact Bonds](victory-bonds.qmd)** - Financing mechanism for lobbying efforts
- **[Financial Plan Overview](financial-plan.qmd)** - Complete fundraising, spending, and treasury management framework

### Campaign Budget Breakdown

The [$1.0B campaign cost](campaign-budget.qmd) (used as denominator in complete case {{< var roi_all_direct_benefits >}}:1 ROI) allocates funds across seven strategic categories:

| Budget Category | Amount | Purpose |
|:---|---:|:---|
| **[Viral Referendum](campaign-budget.qmd)** | [{{< var treaty_campaign_budget_viral_referendum >}}](campaign-budget.qmd) | Global direct democracy campaign, social media amplification, petition platforms |
| **[AI-Assisted Lobbying](campaign-budget.qmd)** | [{{< var treaty_campaign_budget_technology >}}](campaign-budget.qmd) | Automated legislative outreach, personalized constituent messaging, political mapping |
| **[Technology Platform](campaign-budget.qmd)** | [{{< var treaty_campaign_budget_technology >}}](campaign-budget.qmd) | Voting infrastructure, transparency systems, wishocracy implementation |
| **[Legal & Compliance](campaign-budget.qmd)** | [{{< var treaty_campaign_budget_partnerships >}}](campaign-budget.qmd) | International treaty law, regulatory compliance, jurisdictional coordination |
| **[Partnerships](campaign-budget.qmd)** | [{{< var treaty_campaign_budget_partnerships >}}](campaign-budget.qmd) | Coalition building with NGOs, medical organizations, patient advocacy groups |
| **[Operations](campaign-budget.qmd)** | [{{< var treaty_campaign_budget_reserve >}}](campaign-budget.qmd) | Campaign management, communications, logistics, staffing |
| **[Reserve](campaign-budget.qmd)** | [{{< var treaty_campaign_budget_reserve >}}](campaign-budget.qmd) | Contingency for unforeseen challenges and opportunities |
| **Total Campaign Cost** | **[{{< var treaty_campaign_total_cost >}}](campaign-budget.qmd)** | 4-year implementation timeline (amortized: {{< var treaty_campaign_budget_technology >}}/year) |

This budget is designed for a 3-5 year campaign to achieve treaty ratification by major powers, representing less than 4% of the first year's conservative benefits ({{< var combined_peace_health_dividends_annual_for_roi_calc >}}). The campaign cost is a one-time investment with perpetual returns, as the system becomes self-sustaining through the captured peace dividend.

This economic analysis focuses on the return on investment once the system is operational, demonstrating that the intervention generates 463:1 to {{< var roi_all_direct_benefits >}}:1 returns regardless of the specific path to adoption.

## Detailed Technical References

For the rigorous analysis:

- **[dFDA Cost-Benefit Analysis](../appendix/dfda-cost-benefit-analysis.qmd)** - The complete 463:1 ROI breakdown with NPV calculations
- **[Health Dividend](health-dividend.qmd)** - Accessible overview of the 463:1 ROI
- **[Economic Value of Accelerated Treatments](../appendix/economic-value-of-accelerated-treatments.qmd)** - The 7-year access acceleration math
- **[Economic Models Notebook](../economics/economic_models.ipynb)** - All calculations you can verify yourself
- **[1% Treaty Cost-Effectiveness](../appendix/1-percent-treaty-cost-effectiveness.qmd)** - Why this is a dominant health intervention

## Risk Analysis and Mitigation

### Implementation Risks

**Political Risk**: Treaty adoption requires coordination across multiple national governments

- *Mitigation*: Dual-track approach combining grassroots referendum with diplomatic engagement (see [Treaty Adoption Strategy](../strategy/treaty-adoption-strategy.qmd))
- *Precedent*: Historical military spending reductions have occurred during periods of public mobilization (post-WW2, post-Cold War)

**Technical Risk**: dFDA platform development and scaling challenges

- *Mitigation*: Phased rollout beginning with proven platforms (similar to RECOVERY trial model); open-source architecture enabling distributed development
- *Validation*: Oxford [RECOVERY trial](../appendix/recovery-trial.qmd) demonstrated 82x cost reduction at scale (11,000+ participants, 6 treatment arms, {{< var dfda_opex_regulatory >}} total cost)

**Adoption Risk**: Insufficient patient enrollment in decentralized trials

- *Mitigation*: Economic incentives (free treatment + compensation); improved trial accessibility; democratized research priorities
- *Evidence*: Current clinical trial participation ([0.06% of population](../appendix/clinical-trial-participants.qmd)) limited by access barriers, not willingness

**Financial Risk**: Insufficient funding to achieve referendum threshold and political mobilization

- *Mitigation*: Multi-stage fundraising with milestone-based releases; diversified funding sources; assurance contracts
- *Conservative threshold*: [280M votes](../references.qmd#3-5-rule) ([3.5% of global population](../references.qmd#3-5-rule)) through viral referendum mechanics

See [Investor Risk Analysis](../appendix/investor-risk-analysis.qmd) for complete risk assessment and sensitivity analysis.

### Governance and Accountability

**DIH Treasury Governance**: [Wishocratic system](../solution/wishocracy.qmd) enabling democratic allocation of research funding

- [8 billion potential participants](../solution/wishocracy.qmd) (any human) vs. current centralized decision-making ([200 NIH staff](../references.qmd#nih-decision-makers-200-people))
- Quadratic voting mechanism prevents plutocratic capture
- Transparent, auditable allocation via blockchain-based system

**dFDA Platform Governance**: Decentralized autonomous organization (DAO) structure

- Open-source protocols ensuring transparency and reproducibility
- Distributed validation preventing single-point failures
- Regulatory compliance framework integrating with national authorities

**Financial Accountability**: Independent oversight and reporting

- Annual third-party audits of DIH treasury and dFDA operations
- Public reporting of all expenditures and outcomes
- Milestone-based funding releases tied to measurable objectives

See [Governance Framework](../appendix/governance.qmd) and [Legal Compliance Framework](../appendix/legal-compliance-framework.qmd) for complete governance structures.

## Conclusion

This economic analysis demonstrates that redirecting 1% of global military spending to medical research through the Decentralized Institutes of Health and Decentralized FDA system generates return on investment ranging from 463:1 (conservative estimate) to {{< var roi_all_direct_benefits >}}:1 (complete estimate), depending on analytical scope.

**Key Findings**:

- **Self-funding structure**: Zero net new spending required (funds redirected from existing military budgets)
- **Dominant intervention**: Simultaneously reduces costs and improves health outcomes
- **Conservative ROI**: [463:1](../appendix/dfda-cost-benefit-analysis.qmd) based solely on R&D efficiency gains

$$
\frac{\$249.3\text{B NPV benefit}}{\$538\text{M NPV cost}} = 463:1
$$

(see [dFDA Cost-Benefit Analysis](../appendix/dfda-cost-benefit-analysis.qmd))

- **Complete ROI**: {{< var roi_all_direct_benefits >}}:1 including all eight quantifiable benefit categories ([{{< var total_complete_benefits_annual >}} annual benefit](../appendix/dfda-cost-benefit-analysis.qmd))
- **Lives saved**: [{{< var treaty_total_lives_saved_annual >}} annually](../appendix/1-percent-treaty-cost-effectiveness.qmd) at net societal benefit of [$6.56M per life](../appendix/1-percent-treaty-cost-effectiveness.qmd)
- **Political feasibility**: Positive economic incentives across all major stakeholder groups

**Comparative Context**: This intervention rivals or exceeds the cost-effectiveness of history's most successful public health achievements (see [Intervention Comparison Table](../appendix/intervention-comparison-table.qmd) for detailed ROI comparisons including smallpox eradication and childhood vaccinations) while requiring no ongoing charitable funding.

**Implementation Pathway**: Phased approach beginning with global referendum and political mobilization, proceeding through treaty adoption, DIH establishment, and dFDA deployment over [36 months](../strategy/roadmap.qmd) (see [Roadmap](../strategy/roadmap.qmd) for complete implementation timeline).

The economic case is grounded in conservative assumptions, validated against peer-reviewed evidence (particularly the [Oxford RECOVERY trial](../appendix/recovery-trial.qmd)), and subjected to comprehensive [sensitivity analysis](../appendix/1-percent-treaty-cost-effectiveness.qmd). The methodology employs standard health economics frameworks (NPV, QALYs, ICER) to enable comparison with existing interventions and facilitate foundation grant evaluation processes.